	Application No.	Applicant(s)	-
	10/609 522	ASAKO ET AL.	
Notice of Allowability Ex	10/608,533 Examiner	Art Unit	
	Vong D. Bok	1652	
	Yong D. Pak	1052	
The MAILING DATE of this communication apperature All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED or other appropriate comm IGHTS. This application is	in this application. If not included nunication will be mailed in due course. THIS	
1. 🔀 This communication is responsive to the amendment filed	on April 11, 2006.		
2. The allowed claim(s) is/are 1 and 15.			
 Acknowledgment is made of a claim for foreign priority ur a)	nder 35 U.S.C. § 119(a)-(d	or (f).	
 Certified copies of the priority documents have 			
Certified copies of the priority documents have	• •		
3. Copies of the certified copies of the priority do	cuments have been receive	ed in this national stage application from the	
International Bureau (PCT Rule 17.2(a)).			
* Certified copies not received:	•		
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		e a reply complying with the requirements	
4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give			
5. CORRECTED DRAWINGS (as "replacement sheets") mus	st be submitted.		
(a) ☐ including changes required by the Notice of Draftspers	on's Patent Drawing Revie	ew (PTO-948) attached	
1) hereto or 2) to Paper No./Mail Date			
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date	s Amendment / Comment o	or in the Office action of	
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t			
6. DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT			
Attachment(s)	E □ Nation of I	nformal Datant Application (DTO 152)	
 Notice of References Cited (PTO-892) Notice of Draftperson's Patent Drawing Review (PTO-948) 		nformal Patent Application (PTO-152)	
2. Motice of Dranperson's Patent Drawing Review (P10-546)		Summary (PTO-413), ./Mail Date	
 Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 	98), 7. ⊠ Examiner	s Amendment/Comment	
4. Examiner's Comment Regarding Requirement for Deposit	8. 🗌 Examiner	s Statement of Reasons for Allowance	
of Biological Material	9. 🗌 Other		

Application/Control Number: 10/608,533

Art Unit: 1652

DETAILED ACTION

Page 2

The amendment filed on April 11, 2006, amending claims 1 and 15 canceling claims 2-8 and 17-18, has been entered.

Claims 1, 9-16 and 19-22 are pending. Claims 9-14, 16 and 19-22 are withdrawn. Claims 1 and 15 are under consideration.

Response to Arguments

Applicant's amendment and arguments filed on April 11, 2006, have been fully considered and are deemed to be persuasive to overcome the rejections previously applied. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Callahan June 12, 2006.

The application has been amended as follows:

IN THE CLAIMS:

Replace claims 1 and 15 with the following.

Application/Control Number: 10/608,533

Art Unit: 1652

--1. An isolated <u>β-keto acid</u> reductase comprising [an] <u>the</u> amino acid sequence of SEQ ID NO:1 except that: the amino acid at amino acid position 245 is <u>substituted with</u> arginine, the amino acid at amino acid position 271 is <u>substituted</u> <u>with</u> aspartic acid, or both the amino acid<u>s</u> at amino acid position 245 [is] <u>and 271</u> are substituted with arginine and [the amino acid at amino acid position 271 is]

Page 3

aspartic acid, respectively. -

--15. A method for modifying [an enzyme] <u>a β-keto acid reductase</u>, which [comprises] <u>consists of</u> substituting [at least] one of the amino acid at positions 245 [and] <u>or</u> 271 of the amino acid sequence of SEQ ID NO:1 [respectively] with another amino acid, wherein the amino acid at position 245 is substituted with arginine and the amino acid at amino acid position 271 is substituted with aspartic acid <u>and wherein the modified β-keto acid reductase continues to have</u> β-keto acid reductase activity.--

Cancel claims 9-14, 16 and 22.

Allowable Subject Matter

Claims 1 and 15 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably

Application/Control Number: 10/608,533 Page 4

Art Unit: 1652

accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong Pak whose telephone number is 571-272-0935. The examiner can normally be reached 6:30 A.M. to 5:00 P.M. Monday through Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

Yong D. Pak Patent Examiner 1652 Tekchand Saidha

Primary Patent Examiner 1652